Vixarelimab
Pruritus associated with Prurigo Nodularis
Phase (Partnered)Licensed to Roche/Genentech
Key Facts
Indication
Pruritus associated with Prurigo Nodularis
Phase
Phase (Partnered)
Status
Licensed to Roche/Genentech
Company
About Kiniksa Pharmaceuticals
Founded in 2015 and publicly traded on NASDAQ, Kiniksa Pharmaceuticals is dedicated to advancing transformative therapies, with a core focus on cardiovascular diseases. Its key achievement is the 2021 FDA approval and commercial launch of ARCALYST for recurrent pericarditis, providing a critical treatment for a serious inflammatory heart condition. The company's strategy involves leveraging validated immune-modulating pathways, pursuing multiple indications for its assets, and forming strategic collaborations to expand its global reach and pipeline potential.
View full company profile